FTO and acute myeloid leukemia: Compared to previously reported FTO inhibitors FB23-2 and MO-I-500, the novel compounds CS1 and CS2 demonstrated superior efficacy in suppressing AML cell viability, with IC50 values reduced by 10- to 30-fold.